Intervacc AB (publ) announced the initiation of a project with Testa Center, Uppsala, to optimise the development of manufacturing processes for a prototype vaccine in pigs. Intervacc's innovative vaccine technology involves fusing important proteins together in order to protect animals from complex bacterial diseases. The new pig vaccine generated positive results in early proof-of-concept studies where the consumption of colostrum from vaccinated sows provided significant levels of protection to piglets at 4 and 7 weeks of age against meningitis, septicaemia and arthritis following challenge with a virulent strain of Streptococcus suis.

Testa Center provide businesses with a modern, pilot-scale testbed to optimise the scale-up processes required to manufacture biologics. The new "on-boarding" project provides a grant to Intervacc of about SEK 118 kSEK, which represents 50% of the "on-boarding" costs for this project that aims to optimise the laboratory-scale production of a recombinant fusion protein in the vaccine in preparation for its transfer to the small-scale production facilities at Testa Center.